KRAS and pancreatic ductal adenocarcinoma: (89) found that KMT2C is frequently mutated in KRAS wild-type tumor samples of pancreatic ductal adenocarcinomas, providing a new promising therapeutic target for the targeted treatment of KRAS wild-type PDAC patients.